丘小庆教授NATURE/BIOTECH.文章的学术价值



所有跟贴·加跟贴·新语丝读书论坛http://www.xys.org/cgi-bin/mainpage.pl

送交者: Godfather 于 2006-1-27, 18:34:35:

截止今日, 该文的引用情形如下(共5篇):

#1
Author(s)
McNamara-P-J, Bayer-A-S.
Author affiliation
Reprints from: P J McNamara, Univ Wisconsin, Dept Med Microbiol & Immunol, Sch Med, 1300 Univ Ave, Biochem Bldg, Room 250, Madison, WI 53706, USA.
Research addresses: Univ Wisconsin, Dept Med Microbiol & Immunol, Sch Med, Madison, WI 53706, USA;
Univ Calif Los Angeles, LA Biomed Res Inst, Torrance, CA 90502, USA;
Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024, USA.
Email: pjmcnamara@facstaff.wisc.edu.
Title
A rot mutation restores parental virulence to an agr-null Staphylococcus aureus strain in a rabbit model of endocarditis.
Source
INFECTION-AND-IMMUNITY, 2005, V73, N6, JUN, pp 3806-3809
ISSN: 0019-9567.
Language
EN.
Abstract
Mutations in rot restore in vitro toxin production to agr-negative strains of Staphylococcus aureus. We show that a rot mutation returns wild-type virulence to an agr mutant, as measured in experimental endocarditis infections by target organ bacterial counts. Implications of our data are discussed in terms of agr antagonist strategies.
Number of cited refs.
30 references.

#2
Author(s)
Garcia-Lara-J, Masalha-M, Foster-S-J.
Author affiliation
Reprints from: J Garcia-Lara, Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Firth Court, Sheffield S10 2TN, S Yorkshire, England.
Research address: Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.
Email: s.foster@sheffield.ac.uk.
Title
Staphylococcus aureus: the search for novel targets.
Source
DRUG-DISCOVERY-TODAY, 2005, V10, N9, MAY 1, pp 643-651
ISSN: 1359-6446.
Language
EN.
Abstract
In the UK, 20,000 cases of Staphylococcus aureus bacteraemia are reported each year, half of which are antibiotic resistant and similar to 4% are fatal, exemplifying a worldwide phenomenon of tremendous economic and human impact. Novel treatments and prophylaxis are urgently required to combat such a serious threat. A common goal in the postgenomic era is to identify new targets for drug intervention (using small molecules) and immunologicals. Several promising cellular targets are now being developed in the quest to control such a life-threatening pathogen.
Number of cited refs.
88 references.

#3
Author(s)
Qiu-X-Q, Zhang-H, Wang-H, Wu-G-Y.
Author affiliation
Reprints from: G Y Wu, Univ Connecticut, Ctr Hlth, Dept Med, Div Gastroenterol Hepatol, Rm AM-044,263 Farmington Ave, Farmington, CT 06030, USA.
Research addresses: Univ Connecticut, Ctr Hlth, Dept Med, Div Gastroenterol Hepatol, Farmington, CT 06030, USA;
W China Hosp, Lab Biomembrane & Membrane Prot, Chengdu, Peoples R China;
W China Second Univ Hosp, Genet Lab, Chengdu, Peoples R China;
Sichuan Univ, Chengdu 610064, Peoples R China.
Email: wu@nso.uchc.edu.
Title
A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis.
Source
ANTIMICROBIAL-AGENTS-AND-CHEMOTHERAPY, 2005, V49, N3, MAR, pp 1184-1189
ISSN: 0066-4804.
Language
EN.
Abstract
A novel antienterococcal peptide was prepared by fusing the enterococcal cCF10 pheromone to the channel-forming domain of colicin Ia, forming Enterococcus faecalis pheromonicin (PMC-EF). This peptide was bactericidal against vancomycin-resistant Enterococcus faecalis (VRE) organisms. Electron microscopy and vital dyes confirmed increased membrane permeability. All mice made bacteremic with VRE strains survived when they were treated with PMC-EF, while all controls died.
Number of cited refs.
17 references.
#4
Accession number & update
000227162100012 20050310.
Author(s)
Gillor-O, Nigro-L-M, Riley-M-A.
Author affiliation
Reprints from: O Gillor, 4326 Osborn Mem Lab, 165 Prospect St, New Haven, CT 06511, USA.
Research address: Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06511, USA.
Email: Osnat.gillor@yale.edu.
Title
Genetically engineered bacteriocins and their potential as the next generation of antimicrobials.
Source
CURRENT-PHARMACEUTICAL-DESIGN, 2005, V11, N8, pp 1067-1075
ISSN: 1381-6128.
Language
EN.
Abstract
The discovery of penicillin by Fleming in 1928 was an historical milestone in the fight against infectious disease. Over the following fifty years, pharmaceutical companies discovered and developed over 100 antibiotics effective against a wide range of human pathogens. More recently, the dramatic rise in antibiotic-resistant pathogens has stimulated renewed efforts to identify, develop or redesign antibiotics active against these multi-resistant bacteria. This review focuses on such efforts directed at one large and highly diverse family of toxins, the bacteriocins, which hold great promise as the next generation of antimicrobials. The majority of bacteriocins differ from traditional antibiotics in one critical way: the), have a relatively narrow killing spectrum and are, therefore, toxic only to bacteria closely related to the producing strain. Accordingly, they can be considered "designers drugs" that target specific bacterial pathogens. In this review we focus on recent attempts to generate custom designed bacteriocins using genetic engineering techniques. These efforts illustrate the potential of genetically-modified bacteriocins to solve some of the most challenging problems in disease control.
Number of cited refs.
115 references.

#5
Author(s)
Bayley-H, Jayasinghe-L.
Author affiliation
Reprints from: H Bayley, Univ Oxford, Dept Chem, Oxford OX1 3TA, England.
Research address: Univ Oxford, Dept Chem, Oxford OX1 3TA, England.
Email: hagan.bayley@chem.ox.ac.uk.
Title
Functional engineered channels and pores - (Review).
Source
MOLECULAR-MEMBRANE-BIOLOGY, 2004, V21, N4, JUL, pp 209-220
ISSN: 0968-7688.
Language
EN.
Abstract
Significant progress has been made in membrane protein engineering over the last 5 years, based largely on the redesign of existing scaffolds. Engineering techniques that have been employed include direct genetic engineering, both covalent and non-covalent modification, unnatural amino acid mutagenesis and total synthesis aided by chemical ligation of unprotected fragments. Combinatorial mutagenesis and directed evolution remain, by contrast, underemployed. Techniques for assembling and purifying heteromeric multisubunit pores have been improved. Progress in the de novo design of channels and pores has been slower. But, we are at the beginning of a new era in membrane protein engineering based on the accelerating acquisition of structural information, a better understanding of molecular motion in membrane proteins, technical improvements in membrane protein refolding and the application of computational approaches developed for soluble proteins. In addition, the next 5 years should see further advances in the applications of engineered channels and pores, notably in therapeutics and sensor technology.
Number of cited refs.
84 references.


这象是35年来的历史性突破吗? 学术界到底有几人相信它是真的?



所有跟贴:


加跟贴

笔名: 密码(可选项): 注册笔名请按这里

标题:

内容(可选项):

URL(可选项):
URL标题(可选项):
图像(可选项):


所有跟贴·加跟贴·新语丝读书论坛http://www.xys.org/cgi-bin/mainpage.pl